OhmBody launches wearable earpiece to reduce pain and heaviness of periods
Hormone-free, neurostimulation for period relief
A new wearable wellness device that uses neurostimulation to target nerve pathways and relieve menstrual symptoms without drugs or hormones has been launched by OhmBody, the women’s health division of Texas-based neurotechnology company Spark Biomedical.
The device, worn as a discreet earpiece, uses low-frequency stimulation of the vagus and trigeminal nerves — two key players involved in regulating pain, mood, digestion and blood flow. According to the company, this dual activation helps guide the nervous system out of “fight or flight” mode and back toward “rest and digest,” helping the body self-regulate during the most disruptive phase of the menstrual cycle.
Developed by a team of scientists, engineers and women with personal experience of debilitating menstrual symptoms, the OhmBody device offers a non-invasive option for those seeking alternatives to conventional treatments. The device does not rely on hormones or medication and is intended to work in concert with the body’s regulatory systems. The device makers say it helps reduce cramps, reduce unhealthy amounts of menstrual blood loss, and provides support for other disruptive effects of periods like fatigue, gastric discomfort, and emotional fluctuations.
“We didn’t create OhmBody to help you ‘power through’ your cycle. We created it so you don’t have to,” said Amy Gaston, VP of Strategic Growth at OhmBody.
“No more heating pads, doubling up on protection, planning your wardrobe and your life around your period, and pretending everything is fine. It’s time for smarter period care that moves with you.”
Positive feedback
An independent, early-stage clinical trial by the company reported that 88% of participants experienced greater menstrual comfort, with an average 55% reduction in blood loss and a 35% reduction on day one of the cycle. Although a very small sample (16 participants), OhmBody also plans to submit the trial for peer review.
“Our research demonstrates that targeted neurostimulation can modulate autonomic nervous system activity to help regulate common menstrual symptoms,” said Dr. Navid Khodaparast, PhD, Chief Science Officer and co-founder at Spark Biomedical.
“OhmBody leverages this science to provide women with a non-invasive, drug- and hormone-free option for restoring balance and relief during their cycle.”
Each starter kit is priced at $719 and includes the neurostimulation device, seven single-use adhesive earpieces, a connecting cable, and other setup components.
Looking ahead
OhmBody now has a further larger randomized controlled trial is planned for early 2026, designed to generate robust safety and efficacy data, which would also support a de novo submission to the FDA.
And while the main focus for OhmBody is on the US market, further expansion is considered for Europe and elsewhere in 2026.
OhmBody is part of Spark Biomedical’s broader push into wearable neurostimulation technologies. Alongside women’s health, it is a platform working on treatment options for neurological health, hemostasis, and pediatrics.